December 12, 2016
Novartis combination against age-related vision loss fails tests
Novartis was denied bringing its eye drug combination of pegpleranib and Lucentis out of Phase III study for age-related vision…
Pharmaceuticals, Biotechnology and Life Sciences
Novartis was denied bringing its eye drug combination of pegpleranib and Lucentis out of Phase III study for age-related vision…
European Commission (EC) has granted an additional indication for Novartis’s Lucentis (ranibizumab) to treat patients with eye disease due to…